<DOC>
	<DOCNO>NCT02221947</DOCNO>
	<brief_summary>This study do evaluate safety , tolerability potential effectiveness new investigational drug , bryostatin 1 , patient Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Study Evaluate Preliminary Safety , Efficacy , PK PD Bryostatin 1 Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>This study single center , randomize , double-blind , placebo-controlled , parallel group trial patient AD . Each subject enrol trial randomize receive single IV dose 0 ( placebo ) 25 Î¼g/m2 bryostatin . A total 15 subject ( 5 placebo arm 10 treatment arm ) enrol study . The study consist screen evaluation study evaluation divide two segment , inpatient segment outpatient segment . The four-day inpatient segment consist baseline evaluation 1-hour IV infusion study drug follow evaluation multiple evaluation first 72 hr post dose . During outpatient segment , patient follow AEs final evaluation 2 week post dose 4-week telephone safety follow . Evaluations include safety , efficacy , pharmacokinetics , pharmacodynamics assess PKC activity</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>Male female , age 50 85 yr . Females nonchildbearing potential Patient must cognitive deficit present least 1 year meet diagnostic criterion probable Alzheimer 's Disease Dementia NIAAA criterion prodromal Alzheimer 's Disease Mini Mental State Exam score 1626 Ability walk , least assistive device Vision hearing sufficient comply test Normal cognitive social function prior onset dementia , evidence progressive symptom patient informant Consistent caregiver accompany patient visit Sufficient basic education able complete cognitive assessment Living outside institution Dementia due condition AD , include vascular dementia Significant neuroimaging abnormality , previously know discover screen MRI scan , Evidence clinically significant unstable cardiovascular , renal , hepatic , gastrointestinal , neurological , metabolic disease within past 6 month Use drug within 14 day prior randomization unless dose drug condition treat stable least 30 day expect remain stable study Use tobacco product nicotinecontaining product within 3 month Day 1 Use high dose vitamin E , valproic acid Any medical psychiatric condition may require medication surgical treatment study Life expectancy le 6 month Use investigational drug within 2 month prior screen visit Clinically significant neurological disease AD Major depression , alcohol drug dependence suicidality Psychotic episodes require hospitalization antipsychotic therapy 2 week within past 10 year , link AD Agitation sufficient preclude participation trial Epilepsy antiepileptic drug therapy Abnormal laboratory test might point another etiology dementia ; Acute poorly control medical illness Likelihood , accord clinical judgment , transfer nursing home within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Alzheimer 's</keyword>
	<keyword>bryostatin</keyword>
	<keyword>PKC epsilon</keyword>
</DOC>